Amarin Corporation PLC

AMRN

Healthcare Drug Manufacturers General

Amarin Corporation PLC’s revenue for fiscal 2025 (year ended December 2025) was $213.6 million, down 6.55% from fiscal 2024.

Revenue
−20.4%
EPS
+103.1%
Free cash flow
+172.6%

Quarter to September 2026, against a year earlier

11.61 0.03 +0.26%
Market cap
$244.0M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
7/9
ROIC
−16.6%
Net debt / EBITDA
6.4×
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26
ROE

+8 more TTM periods

(8.21%) (7.28%) (5.97%) (4.24%)
Piotroski F-Score
7 6 6 6
ROA
(5.72%) (5.17%) (4.19%) (2.96%)
ROIC
(20.04%) (19.78%) (19.79%) (16.57%)
Return on Tangible Assets
(8.52%) (7.53%) (6.18%) (4.37%)
Average Days of Receivables
216.68 181.95 182.11 231.24
Free Cash Flow per Share
0.32 1.22 0.75 1.79
Free Cash Flow
6.73 25.58 15.57 37.49
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026